Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Peanut Allergy - Overview
Peanut Allergy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Peanut Allergy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Peanut Allergy - Companies Involved in Therapeutics Development
Peanut Allergy - Drug Profiles
Peanut Allergy - Dormant Projects
Peanut Allergy - Discontinued Products
Peanut Allergy - Product Development Milestones
Featured News & Press Releases
Jul 03, 2022: Aimmune Therapeutics to present new data for PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp] at the EAACI Hybrid Congress 2022
Jul 01, 2022: Allergy Therapeutics showcases allergy immunotherapy leadership at Congress of the European Academy of Allergy and Clinical Immunology (EAACI) 2022
Jun 27, 2022: ALK begins clinical trial of its SLIT-tablet for the treatment of peanut allergy
Jun 22, 2022: Intrommune announces expanded scope of phase 1 OMEGA study in adults with peanut allergy
Jun 01, 2022: Intrommune Therapeutics mes ndini Murthy as head of regulatory
May 16, 2022: Prota Therapeutics achieves 51 percent peanut allergy remission rate, first company to validate significant quality of life improvements compared with standard care
May 11, 2022: Intrommune previews Phase II trial design for peanut allergy toothpaste
Apr 25, 2022: Allergy Therapeutics shares positive data on VLP Peanut at the 2022 WAO-BSACI Conference
Apr 06, 2022: INT301 continues to meet safety goals in phase 1 omega study in adults with peanut allergy while reaching phase 2 target maintence dose
Mar 04, 2022: Aravax opens IND for PVX108 Phase 2 trials and strengthens SAB
Mar 01, 2022: Allergy Therapeutics shares positive new data at the 2022 American Academy of Allergy Asthma and Immunology Annual Meeting
Feb 16, 2022: Aimmune Therapeutics announces publication of pooled safety alysis of PALFORZIA treatment for up to 2 years in the Jourl of Allergy and Clinical Immunology
Feb 09, 2022: Prota Therapeutics achieves peanut allergy treatment milestone: groundbreaking clinical trial data demonstrates clinical remission of peanut allergy in paediatric patients
Feb 08, 2022: Intrommune reports positive update from ongoing phase 1 study in peanut allergy
Jan 26, 2022: Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Peanut Allergy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Peanut Allergy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Peanut Allergy - Pipeline by Aimmune Therapeutics Inc, 2022
Peanut Allergy - Pipeline by ALK-Abello AS, 2022
Peanut Allergy - Pipeline by Allakos Inc, 2022
Peanut Allergy - Pipeline by Allergy Therapeutics Plc, 2022
Peanut Allergy - Pipeline by Angany Inc, 2022
Peanut Allergy - Pipeline by Aravax Pty Ltd, 2022
Peanut Allergy - Pipeline by AstraZeneca Plc, 2022
Peanut Allergy - Pipeline by BioLingus AG, 2022
Peanut Allergy - Pipeline by BlueWillow Biologics Inc, 2022
Peanut Allergy - Pipeline by Cambridge Allergy Ltd, 2022
Peanut Allergy - Pipeline by Cour Pharmaceuticals Development Co Inc, 2022
Peanut Allergy - Pipeline by DBV Technologies SA, 2022
Peanut Allergy - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Peanut Allergy - Pipeline by IgGenix Inc, 2022
Peanut Allergy - Pipeline by Inimmune Corp, 2022
Peanut Allergy - Pipeline by InnoUp Farma SL, 2022
Peanut Allergy - Pipeline by Intrommune Therapeutics Inc, 2022
Peanut Allergy - Pipeline by Mabylon AG, 2022
Peanut Allergy - Pipeline by Moonlight Therapeutics Inc, 2022
Peanut Allergy - Pipeline by Novartis AG, 2022
Peanut Allergy - Pipeline by Phlaxis, 2022
Peanut Allergy - Pipeline by Prota Therapeutics Pty Ltd, 2022
Peanut Allergy - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Peanut Allergy - Pipeline by Sementis Ltd, 2022
Peanut Allergy - Pipeline by Ukko Inc, 2022
Peanut Allergy - Pipeline by Vedanta Biosciences Inc, 2022
Peanut Allergy - Pipeline by Virtici LLC, 2022
Peanut Allergy - Dormant Projects, 2022
Peanut Allergy - Discontinued Products, 2022